{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.36","upperLimit":"30.58","value":"23.90"}]}]}],"denomUnitsSelected":"Total Patient-years at Risk","denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"264"}],"units":"Total Patient-years at Risk"}],"description":"A SAE was defined as any adverse event that fulfilled at least one of the following criteria: •Was fatal (results in death) •Was life-threatening •Required in-patient hospitalization or prolongation of existing hospitalization •Resulted in persistent or significant disability/incapacity •Was a congenital anomaly/birth defect •Was medically significant or required intervention to prevent one or other of the outcomes listed above. Multiple events reported in the same participant were counted multiple times in the calculation of incidence. Incidence rate is defined as events per 100 patient years.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with GPA (Wegener's granulomatosis) or MPA who received rituximab as per investigator's discretion were followed for a maximum of 4.32 years.","id":"OG000","title":"Rituximab"}],"paramType":"NUMBER","populationDescription":"The re-treated safety population was a subset of the safety population and included all participants who received more than one course of rituximab.","reportingStatus":"POSTED","timeFrame":"From first dose until participant withdrawal or the date of last participant, last visit (up to 4.32 years)","title":"Incidence Rate of Serious Adverse Events in Participants Who Received Re-treatment With MabThera/Rituximab","type":"SECONDARY","typeUnitsAnalyzed":"Total Patient-years at Risk","unitOfMeasure":"events per 100 patient year"}